Pharma & Biotech Stock Outlook - Aug. 2012 - Zacks Analyst Interviews
News | 09 August 2012
While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. The next few years are expected to reflect a significant imbalance between new product introductions and patent ...
Click on the link to read the full article at NASDAQ
(This link will open in a new window)
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
